[go: up one dir, main page]

WO2002011761A3 - Vaccine against rsv - Google Patents

Vaccine against rsv Download PDF

Info

Publication number
WO2002011761A3
WO2002011761A3 PCT/US2001/041633 US0141633W WO0211761A3 WO 2002011761 A3 WO2002011761 A3 WO 2002011761A3 US 0141633 W US0141633 W US 0141633W WO 0211761 A3 WO0211761 A3 WO 0211761A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
protein
vaccine against
against rsv
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/041633
Other languages
French (fr)
Other versions
WO2002011761A2 (en
Inventor
James J Mond
Gregory Prince
Dennis M Klinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority to AU2001285421A priority Critical patent/AU2001285421A1/en
Publication of WO2002011761A2 publication Critical patent/WO2002011761A2/en
Publication of WO2002011761A3 publication Critical patent/WO2002011761A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a vaccine comprising adjuvanting oligodideoxynucleotides (ODNs), containing at least one CpG dinucleotide and an antigen comprising a peptide sequence bearing at least one epitope of a Paramyxoviridae F protein. In one embodiment, the ODN is admixed or conjugated to an F protein from a respiratory syncytial virus (RSV). The vaccine of the invention may be administered directly to mucosal tissues of the respiratory tract by inhalation or intranasal administration.
PCT/US2001/041633 2000-08-10 2001-08-09 Vaccine against rsv Ceased WO2002011761A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001285421A AU2001285421A1 (en) 2000-08-10 2001-08-09 Vaccine against rsv

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22401100P 2000-08-10 2000-08-10
US60/224,011 2000-08-10
US22930700P 2000-09-01 2000-09-01
US60/229,307 2000-09-01

Publications (2)

Publication Number Publication Date
WO2002011761A2 WO2002011761A2 (en) 2002-02-14
WO2002011761A3 true WO2002011761A3 (en) 2003-01-23

Family

ID=26918345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041633 Ceased WO2002011761A2 (en) 2000-08-10 2001-08-09 Vaccine against rsv

Country Status (2)

Country Link
AU (1) AU2001285421A1 (en)
WO (1) WO2002011761A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
SE0201701D0 (en) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
WO2000062802A2 (en) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccine comprising rsv antigen and cpg oligonucleotide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999061056A2 (en) * 1998-05-22 1999-12-02 Loeb Health Research Institute At The Ottawa Hospital Methods and products for inducing mucosal immunity
WO2000062802A2 (en) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals Sa Vaccine comprising rsv antigen and cpg oligonucleotide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HANCOCK G E ET AL: "CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4874 - 4882, XP004303185, ISSN: 0264-410X *
TEBBEY P W ET AL: "A NOVEL AND EFFECTIVE INTRANASAL IMMUNIZATION STRATEGY FOR RESPIRATORY SYNCYTIAL VIRUS", VIRAL IMMUNOLOGY, MARY ANN LIEBERT, INC., NEW YORK, US, vol. 12, no. 1, 1999, pages 41 - 45, XP001055775, ISSN: 0882-8245 *

Also Published As

Publication number Publication date
AU2001285421A1 (en) 2002-02-18
WO2002011761A2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
WO2001068116A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
ATE250937T1 (en) VACCINE PREPARATIONS CONTAINING CHITOSAN AND INFLUENZA ANTIGEN(S) FOR ADMINISTRATION THROUGH A MUCOSA
WO2001060402A3 (en) Proteosome influenza vaccine
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2002080965A3 (en) Vaccine composition
DE69426077D1 (en) ADJUVANTIES FOR VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
WO2001092470A3 (en) Dna expression vectors and methods of use
WO2002028428A3 (en) Vaccine composition
AR030829A1 (en) A FORMATION OF VACCINE, PROCEDURE FOR THE PRODUCTION OF THE SAME, USE OF SUCH PREPARATION AND A CASE FOR ADMINISTRATION VIA INTRANASAL
AU2002336148A1 (en) Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine
WO2003039595A3 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
EP2066332A4 (en) INFLUENZA VACCINE COMPRISING A MIXTURE OF MANNANE AND ANTIGEN OF INFLUENZA
WO2002087494A3 (en) Novel vaccine
AU2001263443A1 (en) F-protein epitope-based vaccine for respiratory syncytial virus infection
WO2000035481A3 (en) Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
DE69828801D1 (en) PEPTIDE DERIVED FROM THE BINDING (G) PROTEIN OF THE RESPIRATORY SYNZYTIALVIRUS
Hancock et al. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
WO2002058725A3 (en) Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
WO2002011761A3 (en) Vaccine against rsv
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
FI952445A0 (en) Administration through the pneumococcal antigen mucosa
WO2001070265A3 (en) Lipopeptide adjuvants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP